Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective

References

• Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357–761. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357–76
   PubMed Web of Science ®Google Scholar
• Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002;180:227–332. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002;180:227–33
   PubMed Web of Science ®Google Scholar
• Knapp M. Costs of schizophrenia. Br J Psychiatry 1997;171:509–183. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997;171:509–18
   PubMed Web of Science ®Google Scholar
• Rice DP. The economic impact of schizophrenia. J Clin Psychiatry 1999;60 Suppl 1:4–64. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry 1999;60 Suppl 1:4–6
   PubMed Web of Science ®Google Scholar
• Rössler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15:399–4095. Rössler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15:399–409
   PubMed Web of Science ®Google Scholar
• Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000;61 Suppl 13:38–416. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000;61 Suppl 13:38–41
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279–937. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279–93
   PubMed Web of Science ®Google Scholar
• Peuskens J. Clinical effectiveness in adults with chronic schizophrenia. Eur Neuropsychopharmacol 2004;14 Suppl 4:S453–S4598. Peuskens J. Clinical effectiveness in adults with chronic schizophrenia. Eur Neuropsychopharmacol 2004;14 Suppl 4:S453–S459
   PubMed Web of Science ®Google Scholar
• Pompili M, Amador XF, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007;6:109. Pompili M, Amador XF, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007;6:10
   PubMedGoogle Scholar
• Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. J Am Med Assoc 2003;290:1517–910. Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. J Am Med Assoc 2003;290:1517–9
   PubMed Web of Science ®Google Scholar
• Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004;20:139–5411. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004;20:139–54
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132–9112. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132–91
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5–4013. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5–40
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: Treatment of mania. World J Biol Psychiatry 2003;4:5–1314. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: Treatment of mania. World J Biol Psychiatry 2003;4:5–13
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment. World J Biol Psychiatry 2004;5:120–3515. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment. World J Biol Psychiatry 2004;5:120–35
   PubMed Web of Science ®Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121–816. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121–8
   PubMed Web of Science ®Google Scholar
• Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007;22:249–6717. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007;22:249–67
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8:232–4118. Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8:232–41
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30:95–10519. Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30:95–105
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491–50520. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491–505
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763–7121. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763–71
   PubMed Web of Science ®Google Scholar
• Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509–1622. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509–16
   PubMed Web of Science ®Google Scholar
• Peuskens J; on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712–2623. Peuskens J; on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712–26
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley Jr CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457–6524. Tollefson GD, Beasley Jr CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457–65
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, 2nd ed. [online]. Available from http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Bipolar2ePG_05–15–06 [accessed 11 March 2008]25. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, 2nd ed. [online]. Available from http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Bipolar2ePG_05–15–06 [accessed 11 March 2008]
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia [online]. Available from http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2ePG_05-15-06 [accessed 15 August 2005]26. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia [online]. Available from http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2ePG_05-15-06 [accessed 15 August 2005]
   Google Scholar
• Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs 2005;19:27–4227. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs 2005;19:27–42
   Google Scholar
• McEvoy J, Lieberman JA, Perkins D, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050–6028. McEvoy J, Lieberman JA, Perkins D, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050–60
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209–2329. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209–23
   PubMed Web of Science ®Google Scholar
• Buckley PF. Which antipsychotic do I choose next? CATIE Phase 2 offers insights on efficacy and tolerability. Curr Psychiatry 2006;5:27–4330. Buckley PF. Which antipsychotic do I choose next? CATIE Phase 2 offers insights on efficacy and tolerability. Curr Psychiatry 2006;5:27–43
   Google Scholar
• Nasrallah HA. CATIE's surprises: in antipsychotics’ square-off, were there winners or losers? Curr Psychiatry 2006;5:49–6531. Nasrallah HA. CATIE's surprises: in antipsychotics’ square-off, were there winners or losers? Curr Psychiatry 2006;5:49–65
   Google Scholar
• The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. Lenexa (KS): AAPOR; 200432. The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. Lenexa (KS): AAPOR; 2004
   Google Scholar
• Moller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000;1:204–1433. Moller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000;1:204–14
   PubMedGoogle Scholar
• Linden M, Eich FX, Pyrkosch L. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. Int Clin Psychopharmacol 2007;22:175–834. Linden M, Eich FX, Pyrkosch L. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. Int Clin Psychopharmacol 2007;22:175–8
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553–6435. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553–64
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev Neurother 2004;4:S17–S2536. Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev Neurother 2004;4:S17–S25
   PubMedGoogle Scholar
• McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66 Suppl 3:28–3637. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66 Suppl 3:28–36
   PubMed Web of Science ®Google Scholar
• Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. Can Med Assoc J 2005;172:1703–1138. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. Can Med Assoc J 2005;172:1703–11
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, Engelhart LM, Janagap CC, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Investig 2004;24:275–8639. Mahmoud RA, Engelhart LM, Janagap CC, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Investig 2004;24:275–86
   PubMed Web of Science ®Google Scholar
• Locklear J, Perry R. Real world antipsychotic prescribing patterns for schizophrenia treatment across Europe. Eur Neuropsychopharmacol 2007;17:S44740. Locklear J, Perry R. Real world antipsychotic prescribing patterns for schizophrenia treatment across Europe. Eur Neuropsychopharmacol 2007;17:S447
   Web of Science ®Google Scholar
• American Psychiatric Association. APA says CATIE schizophrenia study argues for full range of treatment options [online]. Available from http://www.psych.org/MainMenu/Newsroom/NewsReleases/2005NewsReleases/catie09_20_05study.aspx [accessed 13 August 2007]41. American Psychiatric Association. APA says CATIE schizophrenia study argues for full range of treatment options [online]. Available from http://www.psych.org/MainMenu/Newsroom/NewsReleases/2005NewsReleases/catie09_20_05study.aspx [accessed 13 August 2007]
   Google Scholar
• Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New Engl J Med 1994;331:650–542. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New Engl J Med 1994;331:650–5
   PubMed Web of Science ®Google Scholar
• McCombs JS, Luo M, Johnstone BM, et al. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000;3:222–3143. McCombs JS, Luo M, Johnstone BM, et al. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000;3:222–31
   PubMedGoogle Scholar
• Hellewell JSE. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60 Suppl 23:14–944. Hellewell JSE. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60 Suppl 23:14–9
   PubMed Web of Science ®Google Scholar
• Hugenholtz GW, Heerdink ER, Meijer WE, et al. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005;38:122–445. Hugenholtz GW, Heerdink ER, Meijer WE, et al. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005;38:122–4
   PubMed Web of Science ®Google Scholar
• Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000;34:200–746. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000;34:200–7
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353–947. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353–9
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519–2648. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519–26
   PubMed Web of Science ®Google Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998;59 Suppl 12:17–2249. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998;59 Suppl 12:17–22
   Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415–2750. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415–27
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079–8751. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079–87
   PubMed Web of Science ®Google Scholar
• Altamura AC. Drug-resistance phenomena in major psychoses: their discrimination and causal mechanisms. Clin Neuropharmacol 1990;13 Suppl 1:S1–S1552. Altamura AC. Drug-resistance phenomena in major psychoses: their discrimination and causal mechanisms. Clin Neuropharmacol 1990;13 Suppl 1:S1–S15
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323–3053. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323–30
   PubMed Web of Science ®Google Scholar
• Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41–854. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41–8
   PubMed Web of Science ®Google Scholar
• Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 2006;21:657–6455. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 2006;21:657–64
   PubMed Web of Science ®Google Scholar
• Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227–4056. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227–40
   PubMed Web of Science ®Google Scholar